Literature DB >> 20574943

Stent graft versus balloon angioplasty for failing dialysis access grafts: a long-awaited advance in the treatment of permanent hemodialysis access.

Bart L Dolmatch.   

Abstract

Arteriovenous grafts (AVGs) for hemodialysis have a high failure rate, often due to the development of stenosis at the graft-to-vein anastomosis. Angioplasty (PTA) has been used for over two decades to treat AVG stenosis, with good technical success but limited AVG patency. Results of a prospective multi-center randomized trial, comparing stent graft to PTA in AVGs, has demonstrated superior access circuit patency for the stent graft group. Recent publication of this clinical study brings us into an exciting new era of dialysis access management using covered stents to improve durability of catheter-based therapy.

Entities:  

Mesh:

Year:  2010        PMID: 20574943     DOI: 10.1177/112972981001100201

Source DB:  PubMed          Journal:  J Vasc Access        ISSN: 1129-7298            Impact factor:   2.283


  3 in total

1.  Outcomes of endovascular intervention for salvage of failing hemodialysis access.

Authors:  Terence Lx Tan; Kyin K May; Peter A Robless; Pei Ho
Journal:  Ann Vasc Dis       Date:  2011-06-02

2.  Efficacy of SMART Stent Placement for Salvage Angioplasty in Hemodialysis Patients with Recurrent Vascular Access Stenosis.

Authors:  Shingo Hatakeyama; Terumasa Toikawa; Akiko Okamoto; Hayato Yamamoto; Kengo Imanishi; Teppei Okamoto; Noriko Tokui; Yuichiro Suzuki; Naoki Sugiyama; Atsushi Imai; Yasuhiro Hashimoto; Shigemasa Kudo; Takahiro Yoneyama; Takuya Koie; Noritaka Kamimura; Hisao Saitoh; Tomihisa Funyu; Chikara Ohyama
Journal:  Int J Nephrol       Date:  2011-11-20

3.  Angiotensin Converting-Enzyme Inhibitors, Angiotensin Receptor Blockers, and Calcium Channel Blockers Are Associated with Prolonged Vascular Access Patency in Uremic Patients Undergoing Hemodialysis.

Authors:  Fu-An Chen; Chih-Chiang Chien; Yu-Wei Chen; Yu-Te Wu; Chih-Ching Lin
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.